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Improved treatment outcomes with bedaquiline when substituted for second-line 
injectable agents in multidrug resistant tuberculosis: a retrospective cohort study 
 
Background 
Bedaquiline is used as a substitute for second-line injectable (SLI) intolerance in the 
treatment of multidrug-resistant tuberculosis (MDR-TB), but the efficacy and safety of this 
strategy is unknown. 
 
Methods 
We performed a retrospective cohort study to evaluate treatment outcomes for MDR-TB 
patients who substituted bedaquiline for SLIs. Adults receiving bedaquiline substitution for 
MDR-TB therapy, plus a matched control group who did not receive bedaquiline, were 
identified from the electronic TB register in the Western Cape Province, South Africa. The 
primary outcome measure was the proportion of patients with death, loss to follow up, or 
failure to achieve sustained culture conversion at 12 months of treatment. 
 
Results 
Data from 162 patients who received bedaquiline substitution and 168 controls were 
analyzed; 70.6% were HIV-infected. Unfavorable outcomes occurred in 35/146 (23.9%) 
patients in the bedaquiline group versus 51/141 (36.2%) in the control group (relative risk, 
0.66; 95% confidence interval [CI], 0.46 to 0.95). The number of patients with culture 
reversion was lower in those receiving bedaquiline (1 patient, 0.8%) compared to controls 
(12 patients, 10.3%; P = 0.001). Delayed initiation of bedaquiline was independently 
associated with failure to achieve sustained culture conversion (adjusted odds ratio, 1.5; 
95% CI, 1.1 – 1.9, for every 30-day delay). Mortality was similar at 12 months (11 deaths in 




Substituting bedaquiline for SLIs in MDR-TB treatment resulted in improved outcomes at 12 
months compared with patients who remained on SLIs, supporting the use of bedaquiline 
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In this population with a high rate of HIV co-infection, bedaquiline substitution for second-
line injectable agents was associated with a lower proportion of unfavorable treatment 
outcomes at 12 months compared with a matched control group receiving standard 







Bedaquiline is used as a substitute for second-line injectable (SLI) intolerance in the 
treatment of multidrug-resistant tuberculosis (MDR-TB), but the efficacy and safety of this 
strategy is unknown. 
 
Methods 
We performed a retrospective cohort study to evaluate treatment outcomes for MDR-TB 
patients who substituted bedaquiline for SLIs. Adults receiving bedaquiline substitution for 
MDR-TB therapy, plus a matched control group who did not receive bedaquiline, were 
identified from the electronic TB register in the Western Cape Province, South Africa. The 
primary outcome measure was the proportion of patients with death, loss to follow up, or 
failure to achieve sustained culture conversion at 12 months of treatment. 
 
Results 
Data from 162 patients who received bedaquiline substitution and 168 controls were 
analyzed; 70.6% were HIV-infected. Unfavorable outcomes occurred in 35/146 (23.9%) 
patients in the bedaquiline group versus 51/141 (36.2%) in the control group (relative risk, 
0.66; 95% confidence interval [CI], 0.46 to 0.95). The number of patients with culture 
reversion was lower in those receiving bedaquiline (1 patient, 0.8%) compared to controls 
(12 patients, 10.3%; P = 0.001). Delayed initiation of bedaquiline was independently 
associated with failure to achieve sustained culture conversion (adjusted odds ratio, 1.5; 
95% CI, 1.1 – 1.9, for every 30-day delay). Mortality was similar at 12 months (11 deaths in 
each group; P = 0.973). 
 
Conclusions 
Substituting bedaquiline for SLIs in MDR-TB treatment resulted in improved outcomes at 12 
months compared with patients who remained on SLIs, supporting the use of bedaquiline 
for MDR-TB treatment in programmatic settings.
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INTRODUCTION 
Multidrug resistant tuberculosis (MDR-TB), defined as resistance to rifampicin and isoniazid, 
is associated with increased mortality and worse treatment outcomes as compared with 
drug-susceptible TB.1 Second-line injectable drugs (SLIs), core agents used in the treatment 
of MDR-TB,2 cause substantial toxicity and intolerance which leads to treatment 
discontinuation and contributes to the low success rates with conventional MDR-TB 
treatment.3,4  
 
There is a stepwise decline in the success of TB treatment as drug resistance patterns 
advance,5 and the presence of resistance to SLIs is a significant predictor of poor long-term 
survival in some studies.5,6 Therefore, discontinuing SLIs from MDR-TB regimens without 
replacement by an effective drug may put patients at risk of worse outcomes and ongoing 
transmission of drug-resistant TB.  
 
The novel diarylquinoline, bedaquiline, improves culture conversion rates when added to 
conventional MDR-TB treatment in clinical trials,7-9 and has also been shown to improve 
treatment outcomes in observational studies.10 However, there are safety concerns related 
to its effect on QT interval prolongation and the increased mortality associated with the 
bedaquiline arms in pooled data from phase 2 clinical trials.11 WHO has made a conditional 
recommendation for the use of bedaquiline in adult MDR-TB patients who have limited 
treatment options,12 which may occur in up to two thirds of cases.13 Bedaquiline is now 
being widely used as a substitute in MDR-TB regimens for patients unable to tolerate SLIs,14 
but the efficacy and safety of this strategy is unknown. We conducted a retrospective cohort 
study to determine outcomes for South African patients who received bedaquiline as a 
substitution for SLIs in conventional MDR-TB therapy, with the hypothesis that this would 
not result in inferior outcomes at 12 months compared with patients who did not 
discontinue SLIs.  
 
STUDY POPULATION AND METHODS 
Study population and eligibility criteria 
In September 2015, the Western Cape Provincial Department of Health expanded and 
decentralized bedaquiline access for adults who had confirmed MDR-TB without additional 
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second-line drug resistance who were unable to tolerate SLIs. Under this expanded 
program, which is ongoing, local clinicians made requests for bedaquiline access for 
individual patients to a Provincial Clinical Advisory Committee using a standardized 
application form. If approved, bedaquiline was provided for a minimum of 24 weeks (with a 
loading dose of 400 mg once daily for the initial two weeks followed by 200 mg three times 
per week for 22 weeks). Other drugs in the MDR-TB regimen included moxifloxacin (which 
was replaced by levofloxacin at bedaquiline initiation, due to the greater QT-prolonging 
effect of moxifloxacin), pyrazinamide, ethionamide, high dose isoniazid, ethambutol and 
terizidone. Until late 2017, this standardized MDR-TB regimen was generally administered 
for a total of 18 to 24 months, including the use of an SLI for 6 to 8 months, according to 
South African National Treatment Program guidelines (the World Health Organization 
shorter MDR-TB regimen was introduced in the Western Cape Province in late 2017, after 
the enrolment window for this study). As bedaquiline exposure is reduced by efavirenz co-
administration, HIV-infected patients on efavirenz were switched to either nevirapine or 
lopinavir/ritonavir at bedaquiline initiation. 
 
We screened all applications to the Provincial Clinical Advisory Committee and included 
consecutive cases that received bedaquiline as a substitution for SLIs between October 2014 
and October 2016. We also included a group of control patients with MDR-TB who did not 
receive bedaquiline, matched 1:1 for clinic location and time of treatment initiation within a 
+/- 6-month window. These patients were identified from the South African Electronic Drug-
Resistant Tuberculosis Register (EDRWeb), a web-based network used in the surveillance 
and management of drug-resistant TB in South Africa. Patients younger than 18 years, and 
those with M. tuberculosis strains known to be resistant to aminoglycosides and/or 




The primary outcome measure was the proportion of patients with unfavorable outcomes 
at 12 months, defined as a composite of death, loss to follow up, or treatment failure 
(failure to achieve sustained culture conversion). Sustained culture conversion was defined 
as at least two consecutive negative cultures with the last culture performed 12 months (+/- 
 14 
2 months) after starting antituberculosis treatment, including from patients with negative or 
absent baseline sputum cultures. To account for missing data in the primary outcome 
measure, we created a secondary composite outcome of death, loss to follow up, and a 
modified definition of treatment failure where any positive sputum culture result between 6 
and 12 months after initiation of MDR-TB treatment was regarded as treatment failure. 
Outcomes were censored at 12 months due to limited availability of sputum culture data 
beyond that time. 
 
Time to initial sputum culture conversion was defined as two consecutive negative cultures 
taken at least 30 days apart, in a patient with a positive baseline sputum culture, with the 
collection date of the first negative culture specimen reported as the conversion date. 
Culture reversion was defined as two positive cultures, taken at least 30 days apart, after 
initial sputum culture conversion at any time after starting MDR-TB treatment, as per WHO 
criteria. Patients were considered lost to follow up when there was a gap of more than 1 
month in clinic visits or dispensing of ART or antituberculosis treatment after the last 
recorded health care contact and no further contact by 12 months.  Outcomes data at 18 
months were collected for those patients with sufficient follow-up time. 
 
Sample size estimation 
The sample size estimation was calculated using death as an outcome. This was chosen 
because of the signal of excess mortality in the bedaquiline arm in a clinical trial,9 and 
because our composite primary endpoint of unfavorable outcomes at 12 months has not 
been previously assessed for bedaquiline. Mortality assumptions were based on a 
comparative mortality analysis from South Africa, published in the 2016 WHO Bedaquiline 
Guideline Development Group report.10 With a sample size of 330 patients, we estimated 
that we would have sufficient power (> 80%), at a one-sided a significance level of 2.5%,  for 
a non-inferiority margin of 10% in proportion of deaths at 12 months between the 
bedaquiline group and the standard treatment group (estimated at 20%).  
 
Analysis and reporting 
We calculated the proportions of cases versus controls with the composite primary and 
secondary endpoints of unfavorable outcome at 12 months and compared these outcomes 
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with the c2 test. We also analyzed individual components of the composite outcome as 
binary variables, as well as the proportions with culture reversion, and 18-month outcomes 
where data were available. Logistic regression analysis was performed to adjust for 
potential confounders in the primary outcome, and to evaluate predictors for failure to 
achieve sustained culture conversion in the bedaquiline group. Time to initial sputum 
culture conversion and death was displayed with Kaplan-Meier plots and compared with the 
log rank test; patients lost to follow up or died were censored at 12 months for the time to 
culture conversion analysis. We used a Cox proportional-hazards model with adjustment for 
baseline smear positivity and HIV status to compare the time to culture conversion in the 
two study groups. Statistical analysis was performed using Stata, version 14.2. 
 
Ethics approval 
This study was approved by the Human Research Ethics Committee at the University of Cape 




Data from 330 patients with laboratory-confirmed pulmonary MDR-TB (70.6% HIV-infected) 
were analyzed: 162 cases with bedaquiline substitution and 168 controls who did not 
receive bedaquiline. Demographic and clinical characteristics at the time of initiation of 
MDR-TB therapy are summarized in Table 1. The groups were well-matched besides for age 
which was higher in the bedaquiline group, and CD4 cell count which was lower amongst 
HIV-infected patients in the bedaquiline group.  
 
Management in the bedaquiline group 
Twenty-nine (18.6%) patients did not receive any SLI treatment and initiated bedaquiline at 
a median of 29 days (interquartile range (IQR) 18 – 49, range 0 – 161) after the start of 
MDR-TB treatment. In the other 127 patients for whom this was documented, SLIs were 
stopped at a median of 54 days (IQR) 25 – 82) after TB treatment initiation. There was a 44-
day (IQR 29 – 70, range 11-161) delay from SLI withdrawal to starting bedaquiline. Hearing 
loss was the most common reason for SLI discontinuation, present in 115 (74%) of those 
who switched. SLIs were also discontinued because of renal impairment in 28 (18%) and 
 16 
hypokalemia in 13 (8%) patients.  
 
Outcomes 
The number of patients assessed for the primary outcome is shown in Figure 1. Unfavorable 
outcome according to the primary composite measure was assessed in 287 (87%) patients 
(146 in the bedaquiline group and 141 controls). This outcome occurred in 35 (23.9%) 
patients in the bedaquiline group versus 51 (36.2%) patients in the control group (relative 
risk (RR), 0.66; 95% confidence interval [CI], 0.46 to 0.95; P = 0.024). The odds of 
unfavorable outcomes remained significantly lower in the bedaquiline group after adjusting 
for age, CD4 count, HIV status, and baseline smear positivity in a multivariate logistic 
regression model (adjusted odds ratio [aOR] 0.38; 95% CI, 0.18 to 0.81). Bedaquiline use was 
associated with a protective effect of similar magnitude when almost the full cohort (n = 
310) was assessed for the secondary composite outcome, where 44 (27.9%) patients in the 
bedaquiline group versus 58 (38.2%) in the control group had unfavorable outcomes at 12 
months (RR, 0.73; 95% CI 0.53 to 1.0; P = 0.053). 
 
As shown in Table 2, the proportion of deaths in the bedaquiline group (11 deaths, 7.6%) 
was non-inferior to the control group (11 deaths, 7.5%) at 12 months (risk difference 0.1%; 
95% CI, -5.9 to 6.1; within the pre-specified non-inferiority limit of 10%). The reduction in 
unfavorable outcomes with bedaquiline use was mainly influenced by differences in 
sustained culture conversion rates: only 7 (5.9%) patients switched to bedaquiline failed to 
achieve sustained culture conversion at 12 months compared with 19 (17.4%) in the control 
group, P = 0.006. The effect of bedaquiline on sustained culture conversion persisted at 18 
months (Table 2). A total of 13 (5.4%, n = 241) patients with a positive baseline culture 
reverted to culture-positive after initial culture conversion (i.e. two consecutive negative 
sputum cultures), at a median time of 263 days (IQR 217 – 296) from the start of treatment. 
The number of patients with culture reversion was significantly lower in the bedaquiline 
group (1 patient, 0.8% vs. 12 patients, 10.3% in the control group; P = 0.001). The 
proportion of cases with missing culture reversion outcome data was not different between 
the groups (P = 0.097). 
 
In the bedaquiline group, the proportion of HIV-infected patients with unfavorable 
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outcomes at 12 months (20 (20.0%), n = 100) was not significantly different to HIV-
uninfected patients (15 (32.6%), n = 46; P = 0.143). This included mortality, with 5 (5.1%) 
deaths amongst HIV-infected and 6 (12.8%) deaths amongst HIV-uninfected patients (P = 
0.176). On univariate analysis, shown in Table 3, timing of initiation of bedaquiline from the 
start of MDR-TB treatment was the only factor associated with failure to achieve sustained 
sputum culture conversion at 12 months (unadjusted OR, 1.4; 95% CI, 1.1 – 1.9 for every 30-
day delay). This remained an independent predictor after adjustment for comorbidities and 
HIV status (aOR, 1.5; 95% CI, 1.1 – 1.9). 
 
Amongst those with positive sputum cultures at baseline (n = 290), 87.4% (95% CI, 81.1 to 
92.4) in the bedaquiline group had achieved sputum culture conversion by 6 months versus 
78.3% (95% CI, 71.0 to 85.0) in the control group; crude hazard ratio (HR) for culture 
conversion in the bedaquiline group 1.32; 95% CI, 1.02 to 1.71; P = 0.032, Fig. 2). This effect 
persisted after adjusting for HIV status and baseline sputum smear positivity (adjusted HR, 
1.32; 95% CI 1.00 to 1.76; P = 0.048). The median time to death within 12 months of 
initiation of TB treatment was not different between bedaquiline-exposed and -unexposed 
patients (P = 0.962, Fig. 3). 
 
DISCUSSION 
In this population with MDR-TB and a high burden of HIV co-infection, substituting 
bedaquiline for SLIs resulted in fewer unfavorable outcomes after 12 months of treatment 
compared with regimens containing an SLI for its full course. To our knowledge this is the 
first study to specifically evaluate a strategy of bedaquiline substitution for SLIs in 
conventional MDR-TB therapy.  
 
Our results are consistent with those from other observational studies assessing the efficacy 
of bedaquiline in clinical practice.15,16 A WHO meta-analysis evaluating the use of 
bedaquiline amongst 391 patients with drug-resistant TB, including XDR-TB, showed that 
almost 80% had culture converted at 6 months and that treatment success was achieved in 
69%.10 Importantly, in our study the number of patients with culture reversion was 
significantly lower in those switched to bedaquiline, suggesting a persistent effect after 
stopping the 6-month course, in keeping with its long terminal elimination half-life.17 These 
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findings lend support to the use of bedaquiline in shorter MDR-TB regimens, although this 
needs to be evaluated in prospective studies with longer term follow-up to assess true 
relapse. 
 
The 12-month outcomes observed in the control arm of our study were better than the 
expected treatment success rates with conventional MDR-TB therapy of ~54% in 
programmatic settings.1,18 However, the standard definition of treatment success involves a 
longer follow up duration to treatment completion, which was not assessed in our cohort, 
and could account for this discrepancy19. The external validity of our findings is supported 
by a recent systematic review which found similar 6-month culture conversion rates (75%; 
95% CI, 60–90) with the use of standardized treatment regimens for MDR-TB.18  
 
The mortality associated with MDR-TB is consistently around 15%,1,20 similar to the 
proportion of deaths observed in our cohort at 18 months. The meta-analysis conducted by 
WHO found a 10.6% overall mortality with the use of bedaquiline,10 but with a large degree 
of heterogeneity between populations, ranging from ~6.8% in a French cohort15 to ~20% in 
the South African Bedaquiline Clinical Access Program (BCAP).10 Unlike in our study, which 
included only patients with MDR-TB, most patients in those cohorts had MDR-TB with 
additional resistance to second line agents, limiting conclusions that can be drawn from 
direct comparison.  
 
It is reassuring that there were no differences in the 12- and 18-month mortality rates 
between bedaquiline-exposed and -unexposed patients in our study. In a phase 2b trial, 
which found a significantly higher mortality with bedaquiline use compared to placebo, 
almost all deaths occurred after 6 months, at a median time of 49 weeks after stopping 
bedaquiline.9 Bedaquiline undergoes extensive tissue distribution with intracellular 
accumulation resulting in an extremely long elimination half-life.17,21 The impact of these 
pharmacokinetic characteristics on QT prolongation and other toxic effects is unknown, and 
this is an important area for future research and pharmacovigilance. 
 
Only 138 HIV-infected patients were included in the WHO meta-analysis, and of concern, 
these patients appeared to have a higher mortality compared to HIV-uninfected patients on 
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bedaquiline (13% vs. 9%, respectively).10 In our study, which included 110 HIV-infected 
patients on bedaquiline, we found no difference in 12-month mortality compared with 
those who were HIV-uninfected. This may be related to the relatively high proportion of 
patients on ART (85%), and is consistent with a previous report from the South African BCAP 
that bedaquiline can be used successfully in HIV-infected patients receiving ART.16 
 
In our cohort, later initiation of bedaquiline after the start of MDR-TB treatment was 
independently associated with failure to achieve sustained culture conversion at 12 months. 
Maintaining effective systems for decentralized bedaquiline implementation is challenging 
and will require continuous monitoring and review. 
 
This study has important limitations. The retrospective design introduces sources of bias, 
particularly in the selection of cases. For example, the process used by the Provincial Clinical 
Advisory Committee to evaluate applications may have systematically allocated patients 
with different disease characteristics to the bedaquiline group; this is possibly reflected by 
the older age and lower CD4 cell counts in those patients. But this would tend to bias 
toward worse outcomes in the bedaquiline group, raising the possibility that bedaquiline 
could have an even larger effect on treatment efficacy in an unselected population. 
Adjustment for potential confounders did not change the effect of bedaquiline on reduction 
of unfavorable outcomes. We minimized selection bias by including consecutive applications 
for bedaquiline substitution, and by matching cases with control patients for time of starting 
MDR-TB treatment and for clinic location, which would tend to reduce confounding related 
to variations in quality of care between clinics. Although baseline characteristics were 
similar, our inability to perform adjustment for variables known to have prognostic 
significance (such as radiographic abnormalities and weight) is an additional limitation. 
 
This study involves one of the largest published cohorts to describe the programmatic use of 
bedaquiline, but difficulties in ascertaining outcomes data retrospectively limited the power 
and accuracy of our primary endpoint. Data on the composite primary endpoint was missing 
for 43 (13%) patients, mainly because of restricted access to the national death registry and 
incomplete follow up culture results. However, the proportion of cases with missing 
outcomes data was similar between the groups, and we were able to verify the internal 
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validity of the primary outcome by showing similar results with the use of a secondary 
outcome measure, which included a more conservative definition of treatment failure (any 
positive sputum culture result after month 6 of treatment) that evaluated almost the entire 
cohort (n = 310).  
 
Another limitation is the possibility of immortal time bias conferring an early survival 
advantage on the bedaquiline group.22 This is due to the initial period of observation time 
before SLI substitution when the primary outcome cannot occur in the bedaquiline group, as 
opposed to controls who entered the study from start of MDR-TB treatment. However, 
early mortality (as shown in Figure 3) was relatively low and not significantly different 
between the groups, suggesting limited bias towards survival in the bedaquiline group.  
 
We were not able to obtain specific safety data related to bedaquiline use. Although 
pharmacovigilance is in place, the decentralization of bedaquiline use across many sites 
made obtaining ECG recordings unfeasible with the available resources for this study. 
Reassuringly, accumulating safety data from prospective observational studies suggest that 
the association with QT prolongation has not translated into adverse clinical outcomes.10,23 
 
CONCLUSIONS 
Substituting bedaquiline for SLIs in the programmatic treatment of MDR-TB is not 
associated with increased mortality, and results in fewer unfavorable outcomes at 12 
months compared with patients who remain on SLIs. The improved outcomes with 
bedaquiline use were driven by differences in sustained culture conversion, and reflected by 
the significantly lower rates of culture reversion amongst those patients. Notwithstanding 
the limitations of the study design, these findings provide additional evidence to support 
the routine inclusion of bedaquiline in MDR-TB regimens.24  
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Table 1. Baseline Demographic and Clinical Characteristics 
Variable Bedaquiline 
(N = 162) 
Control 
(N = 168) 
P-value 
Age, years 42 (35-49) 35 (28-42) < 0.001 
Male sex 93 (57.4) 97 (58.1)a 0.901 
Weight, kg 54 (45-62) ND NA 
Any co-morbidity 44 (27.2) ND NA 
HIV-infection 110 (67.9) 94 (74.0)b 0.258 
CD4 count, cells/mm3 97 (45-201) 205 (59-362) 0.007 
Viral load lower than detectable limit 46 (63.0)c 50 (72.5)d 0.229 
On ART 94 (85.5)e ND NA 
Previous TB (any) 88 (63.3)f 95 (56.6) 0.229 
Extra-pulmonary TB 18 (11.4)g 13 (7.8)a 0.268 
Sputum culture positive 142 (87.7) 148 (88.1) 0.902 
Sputum Xpert MTB/RIF positive 111 (68.5) 112 (66.7) 0.719 




• inhA 33 (55.9) ND NA 
• katG 16 (27.1) ND NA 
• Both 2 (3.4) ND NA 
ND = no data; NA = not applicable 
Data are n (%) or median (interquartile range); the data for ART, CD4, and 
viral load apply only to HIV-infected patients (n  204), and were recorded 
the at start of MDR-TB or bedaquiline treatment. P-values calculated using 
Wilcoxon rank-sum test for continuous variables and c2 test for binary 
variables. 
a. n = 167; b. n = 127; c. n = 73; d. n = 69; e. n = 110; f. n = 139; g. n = 158; h. 
n = 59. 
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n = 162 
Control 
n = 168 
P-Value 
 
At 12 months    












Died 11/145 (7.6) 11/147 (7.5) 0.973 












At 18 months    




Failed to achieve sustained culture 
conversion 
3/93 (3.2) 16/81 (19.8) < 0.001 
Data are no./total no. (%) 
* Defined as: death, loss to follow up, or treatment failure. Outcomes were recorded as 
missing in cases where there was no failure event and ≥ 1 of the components of the 
composite endpoint was absent. 
# Defined as: death, loss to follow up, or modified definition of treatment failure. 
Outcomes were recorded as missing in cases where there was no data for all of the 
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components of the composite endpoint. The difference in the proportion of missing 
culture results between groups was not significant (P = 0.092). 
 Note that the components of the secondary composite outcome do not sum in the 
bedaquiline group due to overlap in outcomes in 2 patients (modified treatment failure 
plus death in one and modified treatment failure plus loss to follow up in the other) 
^ Defined as failure to achieve sustained culture conversion (at least two consecutive 
negative cultures with the last culture performed 12 months (+/- 2 months) after starting 
antituberculosis treatment). Outcomes were recorded as missing in cases where 
sustained culture conversion, as per the prespecified definition, could not be assessed 
due to missing sputum culture results. Proportions with missing sputum results were 
similar between the groups (P = 0.092). 
D Defined as any positive sputum culture result between 6 and 12 months after initiation 
of MDR-TB treatment. Outcomes were recorded as missing in cases where there were no 
sputum culture results available after 6 months of therapy. Proportions with missing 














Sputum smear positive at 
baseline 
1.4 (0.3 – 7.8) 0.669  
Comorbid illness 2.1 (0.5 – 10.2) 0.336 1.6 (0.3 – 9.5) 0.606 
HIV infection 0.3 (0.06 – 1.4) 0.115 0.3 (0.5 – 1.7) 0.173 
Per 30-day delay from 
start of treatment 
1.4 (1.1 – 1.9) 0.007 1.5 (1.1 – 1.9) 0.010 
Goodness-of-fit test P = 0.108 for final multivariate model (baseline smear status did not 









Figure 1. Flow diagram showing screening and inclusion of study population.  
MDR-TB = multidrug-resistant tuberculosis; SLI = second-line injectable drugs.  
# At least two consecutive negative cultures with the last culture performed 12 months (+/- 
2 months) after starting antituberculosis treatment, as per the definition of sustained 
culture conversion for this study. Outcomes were recorded as missing in cases where there 
were insufficient culture results to evaluate sustained culture conversion, as per the 
prespecified definition. The proportion of cases with missing data was not different 
between groups (P = 0.092) 
* The missing data do not sum to this value due to overlap in outcomes (i.e. any failure 












Figure 2. Kaplan-Meier graph of time to initial sputum culture conversion in each study 
group during the first 12 months of therapy. Superimposed on the graph is a plot of the 
median (IQR) time to initiation of bedaquiline after the start of MDR-TB therapy.  
This analysis only includes patients with a positive baseline culture. There was no difference 
between groups in the proportion of patients who were baseline culture-negative (P 














Figure 3. Kaplan-Meier graph of time to death in each study group during the first 12 
months of therapy. Superimposed on the graph is a plot of the median (IQR) time to 
initiation of bedaquiline after the start of MDR-TB therapy.  
Note the truncated scale on the y-axis. Median time to bedaquiline start 2.7 months (IQR 














Appendix 1: Research protocol 
 
Purpose of the study: 
Overall aim:  
To determine the 12-month treatment outcomes of patients with multidrug-resistant 
tuberculosis (MDR-TB) when second line aminoglycoside antibiotics are substituted with 
bedaquiline because of contra-indication or toxicity. 
 
Primary outcome measures: 
Survival, retention in care, and sputum culture conversion of patients with MDR-TB 
accessing bedaquiline as a substitute for second line injectables, including HIV-infected 
patients on antiretroviral therapy (ART), as compared to patients on a standard MDR-TB 
regimen. 
 
Secondary outcome measures: 
1. Baseline characteristics of MDR-TB patients accessing bedaquiline. 
2. Timing of bedaquiline substitution. 
3. Serious adverse events related to bedaquiline use. 
 
Hypothesis 
Substituting bedaquiline (6-month course) for aminoglycosides in the treatment of MDR-TB 
leads to non-inferior outcomes in terms of survival, retention in care and sputum culture 
conversion rates at 12 months of MDR-TB treatment compared with patients who remain 
on aminoglycosides (standard of care). 
 
Background 
Globally, 9.6 million people were estimated to have active tuberculosis in 2014. The African 
Region had 28% of the global cases in 2014, representing the worst global disease burden 
relative to population with 281 cases for every 100,000 people compared with the global 
average of 133.1 South Africa has the 6th highest caseload of tuberculosis cases in the world, 
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and the second highest annual incidence per 100,000 people (after Lesotho). The global 
fight against TB has resulted in positive advances. TB prevalence and mortality in 2015 were 
42% and 47% lower respectively than in 1990.1 Unfortunately, while the number of drug-
susceptible TB cases appears to be decreasing, the proportions of new and previously 
treated TB cases with MDR-TB (defined as resistance to at least two first-line drugs: 
isoniazid and rifampicin)1,8 have remained virtually unchanged in recent years. Globally, an 
estimated 3.3% of new TB cases and 20% of previously treated cases have MDR-TB, and in 
South Africa, these figures are 1.8% and 6.7% respectively.1 This is likely an underestimate. 
The lower reported proportion of MDR-TB among patients with TB in the African region is 
contributed to by poor laboratory facilities for drug-susceptibility testing, poor surveillance 
and reporting, outdated databases and sub-optimal surveys.8 In 2014, there were an 
estimated 480,000 new cases of MDR-TB worldwide. Of those 480,000 new cases, only 
123,000 (approximately a quarter) were detected and reported; this large ‘diagnosis gap’ 
fuels ongoing transmission by undetected cases.1 The spread of MDR-TB is threatening to 
undermine the goal of TB control and elimination by the year 2050 set out by the 
Millennium Development Goals (MDGs) and Stop TB Partnership. 
With timely diagnosis and initiation of correct treatment, most people with TB can be cured. 
But despite the availability of effective treatment TB has remained a leading cause of death 
worldwide. In 2014, TB killed 1.5 million people, of which 1.1 million deaths were among 
HIV-positive people. An estimated 190000 people died of MDR-TB in that year, representing 
a case fatality rate of 40%.1 Treatment success rate among MDR-TB patients have remained 
consistently low since the start of global monitoring. Globally, treatment success rate 
(defined as cure or treatment completion)1 for new and relapse drug-susceptible cases was 
86% in 2013, whereas the treatment success rate for MDR-TB was much lower, at 50% in 
the 2012 cohort.1 Of the 50% of MDR-TB patients who were treated unsuccessfully, 16% 
died, 16% were lost to follow-up, treatment failed for 10% and 8% had no outcome 
information.1 An individual patient data meta-analysis of 9,153 patients showed 54% 
treatment success rate, whereas 15% died, 23% defaulted and 8% failed treatment or 
relapsed.10 In South Africa, 78% of new and relapse cases treated with first line TB therapy 
in 2013, and 49% of MDR-TB cases started on standard National Department of Health MDR 
therapy in 2012 were successfully treated.1 A retrospective review of MDR cases from 
Johannesburg, South Africa showed 46% treatment success rate, 22% mortality rate and 
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22% were lost to follow-up.13 Additionally, this 50% of treatment success rate is actually an 
over-estimate because of the treatment cascade: only a quarter of MDR cases were 
detected, and only 50% of these cases were treated successfully. 
The use of more toxic drugs with poorer efficacy than those used in drug-susceptible TB 
contributes to the poor treatment success rate in drug-resistant TB. It is largely a result of 
high mortality rates, loss to follow-up, and treatment interruptions due to drug toxicity. The 
frequency of adverse events in XDR-TB patients in a South African study was as high as 60%, 
and associated with interruption of therapy, life-threatening reactions, or death in 40% of 
patients. The interruption of key second-line drugs, specifically capreomycin, resulted in 
poorer sputum culture conversion outcomes.11 In a study of a cohort of patients from five 
DOTS-Plus sites in resource-limited settings, 30% of the patients required removal of drug(s) 
from second-line regimen due to adverse events.14 Drug resistance, poor adherence to 
therapy and insufficient treatment duration also result in failure of therapy. Failure to cure 
MDR-TB leads to further amplification of drug resistance leading to the development of 
XDR-TB.8 The treatment of MDR-TB needs to be administered for much longer duration and 
costs substantially more. The optimal duration of treatment is not known, but a minimum of 
18 months after sputum culture conversion has been recommended by WHO 2015 
guidelines. In a meta-analysis, the proportion of patients achieving treatment success was 
better when treatment duration was longer than 18 months and patients received directly 
observed therapy throughout treatment.9 Improved treatment success was also associated 
with the use of at least four effective drugs in the intensive phase and the use of later 
generation quinolones.10 The drug regimens used to treat MDR-TB in South Africa (as per 
2011 and updated 2013 NDoH guidelines) involve the use of second line injectable drugs – 
SLIs (amikacin, kanamycin, capreomycin) for a minimum of 6 months, and for at least 4 
months after sputum culture conversion,4 in line with international guidelines.  
Aminoglycosides have significant adverse effects, notably ototoxicity and nephrotoxicity. A 
retrospective review of 263 HIV-uninfected MDR-TB patients in Turkey showed that 41.8% 
patients developed ototoxicity, occurring at a mean of 4.7 months into treatment. 
Ototoxicity led to the withdrawal of SLIs in up to 50% of cases. Nephrotoxicity was less 
common, occurring in 0.7% of cases.7 Aminoglycoside ototoxicity targets sensory 
neuroepithelium of the cochlea, resulting in loss of hair cells and secondary degeneration of 
the auditory nerve. Hearing loss may progress for weeks after aminoglycosides being 
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stopped owing to its long half-life, and the damage is permanent. Risk factors for developing 
ototoxic hearing loss include cumulative drug dose, duration of treatment, bacteraemia, 
renal or liver failure, certain polymorphisms in mitochondrial DNA, and concomitant 
administration of drugs with a synergistic ototoxic effect.6 A prospective cohort study of 153 
MDR-TB patients with normal hearing at baseline at Brooklyn Chest Hospital, Cape Town, 
showed that 57% developed high-frequency hearing loss following aminoglycoside 
treatment. Furthermore, HIV-infected patients (70%) were more likely to develop hearing 
loss than HIV-uninfected patients (42%).6 Capreomycin is likewise associated with high 
toxicity. It was the likely cause of 44% of drug withdrawal, over 40% of severe adverse 
events, and all adverse event (AE)-related death (hypokalaemia in 1 patient and renal failure 
in 5 others) in a cohort of 115 South African XDR-TB patients.11 Having to withdraw 
aminoglycosides or capreomycin because of toxicity substantially weakens an already poor 
regimen, and essentially results in pre-XDR TB (MDR strains resistant to aminoglycosides or 
fluoroquinolones). Treatment success is lower in MDR-TB with resistance to second-line 
injectable drugs than those without additional resistance.15 
Bedaquiline, a diarylquinoline that inhibits mycobacterial ATP synthase, is the first anti-
tuberculosis drug with novel mechanism of action to be approved for use in TB in 40 years. 
WHO issued interim guidance on the use of bedaquiline in 2013, and by the end of 2014, at 
least 43 countries have reported to have used bedaquiline to treat MDR-TB patients in 
efforts to expand access to treatment. 75% of these patients were from the Russian 
Federation and South Africa.1 This was largely based on a phase 2b trial which showed that 
the addition of bedaquiline to a standard 5-drug MDR-TB background regimen for 24 weeks 
resulted in faster culture conversion and significantly more favorable treatment outcome at 
120 weeks, as compared with those given placebo.2 In this trial bedaquiline was added to an 
aminoglycoside-containing regimen rather than replacing the aminoglycosides. Of concern, 
there were ten deaths in bedaquiline group and only two in the placebo group; its reason is 
unclear.2 The use of bedaquiline is associated with moderate prolongation in the QT 
interval, and the risk is increased when bedaquiline is used in combination with other QT-
interval-prolonging drugs, such as moxifloxacin and clofazimine. Bedaquiline is primarily 
metabolized in the liver by the cytochrome P450 isoenzyme 3A4. Coadministered drugs that 
inhibit CYP3A4 could result in higher bedaquiline concentrations, potentially increasing the 
risk of toxicity such as the QT prolongation. Lopinavir/ritonavir is a potent inhibitor of 
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CYP3A4, and when coadministered with bedaquiline, results in higher plasma bedaquiline 
exposure.16 
Few participants in the phase 2b trial had HIV co-infection, and there is very limited data on 
bedaquiline pharmacokinetics when coadministered long term in patients on antiretroviral 
therapy (ART). This is particularly relevant in sub-Saharan Africa, which has the highest 
global prevalence of HIV co-infection among TB patients, at over 60%. Of the 9.6 million 
people infected with TB in 2014 worldwide, 12% were HIV-infected. The African Region 
accounted for 74% of these cases. In 2014, HIV-associated TB deaths accounted for one 
quarter of all TB deaths and one third of the estimated 1.2 million deaths from HIV/AIDS. In 
South Africa, an estimated 61% of TB cases in 2014 were HIV-infected, and an estimated 
79% of these patients were on or started ART.1 ART improves survival and results in higher 
rates of TB cure in HIV co-infected patients with drug-resistant TB.17 A retrospective cohort 
study from Khayelitsha, South Africa showed no significant difference in treatment response 
among MDR-TB patients with and without HIV infection in a programmatic setting with 
access to ART.12 On the other hand, overlapping toxicities of anti-TB drugs and ART often 
complicate treatment. Nephrotoxicity with the use of tenofovir and aminoglycosides and 
hepatitis when nevirapine and pyrazinamide are coadministered have been reported.17 
Drug-drug interactions with ART, as well as different pharmacokinetics in HIV-infected 
patients on ART are likely to influence bedaquiline treatment outcomes in this population. 
Nevirapine is a moderate inducer of CYP3A4 and may potentially reduce its efficacy, 
however study showed no nevirapine effect on bedaquiline concentrations.16 There are high 
levels of acquired drug resistance in HIV-infected adults with failure of first-line ART in South 
Africa, necessitating switch to second-line therapy.18 The increasing number of patients on 
lopinavir/ritonavir impose a challenge on the use of bedaquiline, as lopinavir/ritonavir 
increases bedaquiline exposure two-fold16. 
The Bedaquiline Clinical Access Programme (BCAP) has made bedaquiline available for 
patients with XDR- or pre-XDR-TB in SA.5 The interim outcomes for the first 91 pre-XDR and 
XDR-TB patients enrolled in the BCAP in SA showed high rates of early sputum culture 
conversion. 76% of patients with 6 months of follow-up had either culture-converted or 
remained culture-negative at 6 months after initiation of bedaquiline. 59% of patients were 
HIV-infected and all patients were on ART at initiation of bedaquiline. Mortality rate was 
5%, and none of the three deaths were probably or possibly related to bedaquiline. In 
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addition, no serious adverse events attributed to bedaquiline were reported. QTc interval 
did not change significantly from baseline, and no severe hepatotoxicity or renal dysfunction 
occurred.3  
In an expanded access programme within the national TB programme in SA, modeled on the 
BCAP, MDR-TB patients who have limited treatment options have now been allowed access 
to bedaquiline (from 2015).5 Within this programme one of the indications for bedaquiline is 
that clinicians can request it for patients with baseline hearing or renal impairment or who 
develop these toxicities while on MDR-TB treatment. Recent SA guideline updates now 
allow for patients who develop these toxicities while on the injectable or who have baseline 
hearing or renal impairment to have the aminoglycoside substituted in their MDR treatment 
regimen with bedaquiline.4 The outcomes of patients in the expanded programme have not 
been formally evaluated. Our hypothesis is that substituting bedaquiline (6 months course) 
for aminoglycosides in the treatment of MDR-TB leads to non-inferior outcomes in terms of 
survival, retention in care and sputum culture conversion rates at 12 months of MDR-TB 
treatment compared with patients who remain on aminoglycosides. The results of this study 
will inform the expanded roll-out of bedaquiline in SA by evaluating its use in routine clinical 
settings in a population with high rates of HIV co-infection. In none of the bedaquiline MDR 
trials to date did bedaquiline replace the injectable, thus this will be the first study (albeit 




Retrospective observational cohort study 
 
Characteristics of the study population 
We will include all patients with a laboratory-confirmed diagnosis of pulmonary MDR-TB 
who have been prescribed bedaquiline as part of the expanded access programme in the 
Western Cape because of aminoglycoside contra-indication or intolerance. The outcomes of 
these patients will be compared with those of patients attending the same clinics during the 
same study period, with a laboratory-confirmed diagnosis of MDR-TB, who received the 
standard second-line anti-TB treatment.  
Inclusion criteria: 
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Age ≥18 years 
Documented intolerance to second line injectables at baseline or during MDR-TB treatment 
necessitating switch to bedaquiline. 
Exclusion criteria: 




Patients will be identified using electronic forms submitted to the provincial BCAP 
committee when clinicians request access to bedaquiline. (Appendix A) The committee 
comprises a number of experts in the treatment of DR-TB, who approve the use of 
bedaquiline as part of an appropriate regimen. Information from these forms are entered 
into an electronic database and stored in the Western Cape Department of Health. 
Provincial DR-TB managers have access to this database, and are co-investigators in this 
study. We will include all adult patients with MDR-TB who receive BDQ as a replacement for 
second-line injectables, from 1st March 2015 till 31st January 2016. The control group will be 
MDR-TB patients attending the same clinics during the same study period, who remain on 
aminoglycosides (standard of care). An existing electronic DR-TB database captures 
information on control patients and is stored with provincial DR-TB managers in provincial 
Department of Health. 
 
Research procedures and data collection methods 
Data will be obtained from the BCAP application source documents, as well as from patient 
medical and National Health Laboratory Service (NHLS) records. The following data will be 
imported from an existing electronic DR-TB database and entered onto an electronic 
database specifically designed for this project: 
• Demographic information and medical co-morbidities 
• Details of TB diagnosis and drug-susceptibility testing 
• HIV status, details of ART, CD4 count and HIV viral loads at start of MDR-TB 
treatment 
• Details of previous and current TB treatment 
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• Baseline and follow-up renal function and hearing assessments 
• Timing of aminoglycoside withdrawal 
• Timing of BDQ initiation and duration of use 
• Documented ECG QTcF values  
• Serious adverse events 
• Monthly sputum culture results 
• Vital status, treatment status, and sputum TB culture status at 12 months after 
initiation of therapy 
 
Analysis plan 
For the primary objective, we will compare the proportion of patients switched to BDQ with 
those on standard MDR-TB treatment that reach the composite outcome of death, loss to 
follow up, and failure to culture convert after 12 months of therapy. We will also describe 
these outcomes individually. The Kaplan Meier method will be used for this comparison of 
the combined death and loss to follow-up outcome. Logistic regression analysis will be 
performed to determine the impact of timing of BDQ substitution and patient 
characteristics on the primary outcomes. We will also describe the frequencies of serious 
adverse events between the two groups. Additional analyses will include time to sputum 
culture conversion over 24 weeks of treatment with bedaquiline, the proportion of patients 
with sputum culture conversion at 24 weeks and 12 months, and the rates of acquired 
resistance to second-line drugs at 12 months. 
 
Power calculations 
As the purpose of this non-inferiority study is to demonstrate that death, culture conversion 
and LTFU are not worse in patients who switched to BDQ from standard treatment 
(aminoglycosides), the sample size estimation was calculated using death as an outcome 
with a non-inferiority limit of 10%, a significance level of 0.05 and 80% power.  To achieve 
80% power to demonstrate non-inferiority difference in proportion of deaths at 12 months 
between BDQ group (estimated at 15%) and standard treatment group (15%), it is estimated 
that a minimum of 158 patients would be required in each treatment group.   It is 
anticipated that the study will enroll a minimum of 158 in each treatment group (total n = 
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316) thus the probability of type 2 error will be minimized. 
 
Ethical issues 
Privacy and confidentiality 
All data will be anonymized on entry into the study database. Each participant will be 
allocated a unique study number for identification, which will be stored in a different 
spreadsheet separate from the database. Confidentiality will be maintained as only the 
MMed candidate will have access to patient medical information after relevant ethical and 
provincial approvals. We will ensure the safety of data by using password-protected 
desktop/laptops as well as encrypted USB flash drives. Once data has been collected, all 
documents with patient identifiers will be removed. 
As this is a retrospective analysis, we request a waiver for the requirement of informed 
consent. No treatment decisions will be changed or influenced by the study. 
 
Risks and benefits 
The benefits of the study will include understanding of the outcomes of MDR-TB patients 
accessing bedaquiline compared with those who remain on standard second-line therapy, 
and filling the knowledge gap of the efficacy of bedaquiline in HIV co-infected population on 
concomitant ART. Furthermore, this study will inform the expanded roll-out of bedaquiline 




We will seek formal provincial approval for this study. We do not foresee major costs being 
incurred during the study. 
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Appendix 4: Reviewer comments and response 
 
Reviewer #1:  
1. I am wondering why no adverse event data is presented in the paper. I imagine that since 
the authors were using an electronic database for cases and controls there was probably not 
great reporting of adverse events (a chronic problem with DR-TB records everywhere). If the 
authors do have adverse event data, it would be important to see it reported here. If not, 
they should mention why not.  
Response 
We were not able to obtain adverse event data related to bedaquiline use, specifically 
information on QT prolongation and hepatotoxicity. The decentralization of bedaquiline use 
across many sites (patients from 51 clinics across the Province were included in the study) 
made obtaining ECG recordings impossible with the available resources for this study, and 
monitoring of liver enzymes is not systematically done. We have mentioned this limitation 
in the revised manuscript as follows: 
“We were not able to obtain specific safety data related to bedaquiline use. Although 
pharmacovigilance is in place, the decentralization of bedaquiline use across many sites 
made obtaining ECG recordings unfeasible with the available resources for this study. 
Reassuringly, accumulating safety data from prospective observational studies suggest that 
the association with QT prolongation has not translated into adverse clinical 
outcomes.10,23”  
2. While the authors clearly define their endpoints, I did not see a rationale for looking at 12 
month outcomes. Was this because most patients would have completed both the injectable 
or BDQ after 6 months and then there were an additional 6 months for follow up? I am 
assuming this is why--and also why the authors looked at culture reversion as a potential 
"proxy" for relapse. But it would be good to see an explicit rationale stated in the paper.  
Response 
The main reason for selecting 12-month outcomes as the primary endpoint was because of 
our expectation that data quality would deteriorate beyond that time point, reducing power 
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to observe meaningful differences between the groups. This was borne out in the data, with 
substantially more missing outcomes data at 18 months due to missing culture results and 
vital status. An explanatory statement has been included in the revised manuscript: 
“Outcomes were censored at 12 months due to limited availability of sputum culture data 
beyond that time.”  
Data from the Preserving Effective TB Treatment Study suggest that 12-month sputum 
culture conversion has reasonable diagnostic performance for predicting treatment success 
in MDR-TB [Kurbatova EV, et al. The Lancet Respiratory medicine. 2015;3(3):201-9]. We 
therefore feel that assessing outcomes at 12 months allowed for a relatively robust 
comparison of outcomes a number of months after completion of bedaquiline (or 
injectables). Culture reversion was chosen as a secondary outcome measure because of its 
recognized use to assess treatment outcomes in MDR-TB [Günther, G., et al. New England 
Journal of Medicine. 2016;375(11): 1103-1105 and Pietersen E, et al. Lancet. 
2014;383(9924):1230-1239], and because we did not ascertain end-of-treatment outcomes.  
3. The authors also note that outcomes data at 18 months were collected for some of the 
patients, but I did not see this reported anywhere.  
Response 
18-month outcomes data are reported in Table 2. This has also now been emphasized in the 
text of the revised manuscript: 
“The effect of bedaquiline on sustained culture conversion persisted at 18 months (Table 2).”  
4. In terms of minor comments, throughout the abstract and the paper the authors keep 
referring to MDR-TB patients "who substituted BDQ". The patients themselves did not 
substitute BDQ but rather they received BDQ as a substitution for the injectable. The authors 
should correct this throughout.  
Response 
Many thanks for pointing this out. It has been corrected in the revised manuscript.  
5. In the introduction, the authors state that "presence of resistance to the injectable is a 
significant predictor of poor long-term survival" and cite an important reference from Korea. 
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However, other studies--including a meta-analysis of more than 9,000 patients on treatment 
for DR-TB--have not shown it to be a predictor of poor outcomes. Thus the authors might 
want to note that "some studies" show it to be a predictor of poor outcomes and that the 
drug is recommended as a core agent in the treatment of MDR-TB.  
Response 
Thank you for this suggestion. An individual patient meta-analysis including data from over 
6,700 patients specifically evaluating this association found a significantly lower odds of 
treatment success with the presence injectable resistance in MDR-TB (aOR 0.6 (95% CI, 0.5– 
0.7)). We have included a reference to this study in the revised manuscript and, as 
suggested, have noted that the association is limited to “some studies”.  
6. Finally, in the conclusion, the authors note that the data on culture reversion give support 
for BDQ in shorter regimens. This is an interesting idea but not one addressed by their data. I 
would either take it out or note that this is an area for further study.  
Response 
We point out in the manuscript that our study did not evaluate the use of bedaquiline in the 
shorter MDR-TB regimen. As suggested, a statement has been added in the discussion to 
emphasize that additional studies are required to address this: 
“These findings lend support to the use of bedaquiline in shorter MDR-TB regimens, although 
this needs to be evaluated in prospective studies with longer term follow-up to assess true 
relapse.”  
Reviewer #2 
1. The 12-month unfavourable outcome rate reaches significance depending on which  
definition was used. It is a pity that the p value is non-significant using the second definition. 
The difficulty is that culture positivity between 6 and 12 months is high predictive of an 
unfavourable outcome (at least for patients on MDR treatment not on bedaquiline). Given 
this consideration, it would be fair to state this upfront in the abstract and modify the 
conclusions appropriately.  
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Response 
The effect of bedaquiline on reducing the rate of unfavorable outcomes was statistically 
significant using the prespecified primary composite outcome measure. A secondary 
composite outcome measure was evaluated, which involved a more conservative modified 
definition of treatment failure, in order to support our conclusions from the primary 
endpoint with a larger sample of the cohort. Using this secondary composite outcome 
measure there was a strong trend in favor of bedaquiline (p = 0.053), with a similar 
magnitude of effect to that observed with the primary composite outcome. Furthermore, 
when data from the composite outcomes were disaggregated, differences in the treatment 
failure component remained statistically significant regardless of the definition used. We 
therefore feel reassured that our conclusions are adequately supported by the data.  
2. More detail is required about the patients that were matched. Were standard prognostic 
features in MDR TB, including HIV status, weight, number of drugs, disease extent taken into 
account when matching patients?  
Response 
As described in the manuscript, matching was done for clinic location and timing of 
initiation of MDR-TB therapy. Data for prognostic factors such as weight and chest x-ray 
changes were unavailable, and we were therefore unable to perform matching for these 
variables. However, our matching strategy appeared to be adequate, and as demonstrated 
in Table 1 other important prognostic baseline characteristics such as HIV status and 
virological suppression, smear positivity, culture status, extrapulmonary TB, and previous 
episodes of TB were similar between groups. The table has been updated to report p-values 
to highlight this, as suggested by the reviewer. During the study period standardized MDR- 
TB regimens were used and the number of drugs and composition of background regimens 
was not different for those who received bedaquiline as a substitute for injectables. This has 
now been emphasized in the revised manuscript.  
3. Were chest radiographs available so patients could be matched for disease severity? If 
not, then this limitation should be stated.  
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Response 
This has been noted as a limitation in revised manuscript: 
“Although baseline characteristics were similar, our inability to perform matching for 
variables known to have prognostic significance (such as radiographic abnormalities and 
weight) is an additional limitation.”  
4. Presentation could be improved by including the p-values in table 1.  
Response 
Thank you for this suggestion: the table has been amended in the revised manuscript.  
5. Several variables bias against the bedaquiline group, e.g. CD4 count, which makes the 
findings of the authors more significant (they allude to this). Should a multi-variable analysis 
not be performed, controlling for confounders so that a more accurate assessment of 
unfavourable outcomes could be made? The same considerations apply for treatment 
failure.  
Response 
A multivariate Cox proportional hazards model was performed for time to sputum culture 
conversion, which showed that the effect of bedaquiline on earlier culture conversion 
persisted after adjusting for HIV status and baseline smear positivity. At the suggestion of 
the reviewer we have now also performed multivariate logistic regression for the composite 
primary endpoint. The odds of unfavorable outcomes remain significantly lower in the 
bedaquiline group with the inclusion of age, CD4 count, HIV status, and baseline smear 
positivity in the model (aOR 0.38; 95% CI, 0.18 to 0.81). This has been reported in the 
revised manuscript.  
6. Figure 2 shows time to initial sputum culture conversion. However, this measure doesn't 
have a good relationship with treatment outcomes. A much better measure would be 6-
month culture conversion and there are several papers recently, including from the Lange 
group, that evaluated this biomarker as a predictor of outcome in patients on conventional 
MDR regimens. The 6-month culture conversion rate should be reported. Perhaps the 
manuscript could be updated to reflect more recent publications and policy?  
 56 
Response 
The proportion of patients achieving 6-month culture conversion was reported in the 
submitted manuscript, both in the text (final paragraph of the results section) and in Figure 
2, showing a consistent effect in favor of the bedaquiline group. As discussed above, data 
from the Preserving Effective TB Treatment Study suggest that 12-month sputum culture 
conversion has an acceptable diagnostic performance for predicting treatment success in 
MDR-TB, and that this is similar to 6-month sputum culture conversion [Kurbatova EV, et al. 
The Lancet Respiratory Medicine. 2015;3(3):201-9]. The same study also showed that time 
to culture conversion was significantly associated with end-of-treatment outcomes. We 
therefore feel that these two prespecified endpoints provide reasonable proxies for 
treatment outcomes and allow for a meaningful comparison of the two treatment 
strategies. We acknowledge the limitations of using proxy outcome measures for treatment 
success in MDR-TB (even 6-month sputum culture conversion has suboptimal specificity) 
and recognize that prospective studies with longer term follow up are required to reach 
more definitive conclusions:  
“the standard definition of treatment success involves a longer follow up duration to 
treatment completion, which was not assessed in our cohort,” and 
“this needs to be evaluated in prospective studies with longer term follow-up to assess true 
relapse.”  
7. The failure to match controls to cases based on prognostic features is a major limitation 
that should be mentioned. Why was this not undertaken?  
Response 
This is addressed under points 2 and 5 above.  
8. The authors have clearly stated the other limitations. Given these considerations, it might 
be reasonable to phrase the conclusions appropriately and in a more cautious and 
preliminary.  
Response 
As the reviewer points out, we have carefully considered and explained the limitations of 
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the study design and have attempted to address any modifiable issues with our analysis 
plan. While we are fully cognisant of the limitations of this study (and have been 
transparent about this in the manuscript), we are confident to make the claim that these 
data contribute additional evidence for the wider use of bedaquiline in MDR-TB therapy. To 
address the reviewer’s concern, we have inserted language in the revised manuscript to 
emphasize the limitations: 
“Notwithstanding the limitations of the study design, these findings provide additional 
evidence to support the routine inclusion of bedaquiline in MDR-TB regimens.”  
 
 
